(Q36431498)

14 August 2017

Phase I study of gemcitabine using a once every 2 weeks schedule (English)

1 reference

14 August 2017

J B Vermorken

1

1 reference

14 August 2017

J P Guastalla

2

1 reference

14 August 2017

S R Hatty

3

1 reference

14 August 2017

D E Seitz

4

1 reference

14 August 2017

B Tanis

5

1 reference

14 August 2017

C McDaniels

6

1 reference

14 August 2017

M D Clavel

7

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 January 1997

1 reference

British Journal of Cancer

14 August 2017

1 reference

14 August 2017

76

1 reference

14 August 2017

11

1 reference

14 August 2017

1489-1493

1 reference

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228173

Phase II study of gemcitabine in patients with advanced pancreatic cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228173

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228173

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228173

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228173

Advanced breast cancer: a phase II trial with gemcitabine

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228173

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228173

Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228173

Cytotoxicity and antitumor activity of 2',2'-difluorodeoxycytidine (Gemcitabine)

30 September 2017

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/9400947

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/9400947

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/9400947

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.1997.583

1 reference

14 August 2017

1 reference

14 August 2017

PubMed publication ID

9400947

1 reference